I: Factors VIII, IX and von Willebrand factor, their molecular and antigenic structure: An overview.- Structure and function of factor VIII.- Molecular etiology of factor VIII deficiency in hemophilia A.- The incidence of factor VIII inhibitors in patients with severe hemophilia A.- Epitope specificity and functional characterization, of factor VIII inhibitors.- Immunogenetics of the human immune response to factor VIII.- Factor IX: Molecular structure, epitopes, and mutations associated with inhibitor formation.- Antibodies to von Willebrand factor in von Willebrand disease.- II. The molecular basis of the human immune response.- B-cell epitopes: Fact and fiction.- Antigen analogs as therapeutic agents.- III: Genetic variation and the immune response.- T-cell receptors in immune responses.- Immunoglobulin heavy chain variable region gene usage in human autoimmune diseases.- IV: Treatment of inhibitors.- Porcine factor VIII therapy in patients with factor VIII inhibitors.- Clinical presentation and management of patients with circulating anticoagulants.- The function of factor VIIa in hemophilia A: An hypothesis.- Clinical update on the use of recombinant factor VII.- Apheresis.- IVIg in the treatment of patients with factor VIII inhibitors.- V: Tolerance to coagulation factors.- Tolerance and intolerance to factor VIII: A clinical perspective.- Immune tolerance to Factor VIII: The international registry data.- Multiple mechanisms of immunologic tolerance: Novel approaches for unresponsiveness.- VI: New approaches to the inhibitor problem.- Variable (V) region-mediated control of autoreactivity to factor VIII.- Hepatic gene therapy for hemophilia B.- Panel discussion on the development of inhibitors: Who and why?.- Panel discussion on the development of inhibitors: Today and tomorrow?.- Poster Session Abstract.